Avalon Pharma Secures Exclusive Pembrolizumab Rights Worth 500M SAR

AVALON PHARMA

AVALON PHARMA

4016.SA

0.00

Middle East Pharmaceutical Industries Co. announced on February 4, 2026, the signing of a strategic commercialization agreement with Bio-Thera Solutions Inc. on February 3, 2026. The 15-year renewable contract grants Middle East Pharmaceutical exclusive rights to register and commercialize Pembrolizumab, a Proposed Keytruda® Biosimilar, across Saudi Arabia and MENA markets, with future manufacturing localization rights. The agreement, valued at over 5% of the company's revenues, is expected to generate incremental revenue of at least 500 million SAR from 2030 onwards, supporting patient access to oncology therapies and aligning with Saudi Arabia's Vision 2030 objectives.

Original announcement:

https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=92968&anCat=1&cs=4016&locale=ar

Attached PDF document link:

https://www.saudiexchange.sa/Resources/fsPdf/25633_5507_2026-02-04_02-23-27_en.pdf

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.